CRODA INTERNATIONAL-UNS ADR Business Summary

Croda International PLC (COIHY) operates a high-margin business model centered on the development and sale of specialty chemical ingredients derived from bio-based raw materials. The company generates revenue through three primary segments: Consumer Care, which provides high-performance actives for beauty and home care; Life Sciences, focusing on drug delivery systems for pharmaceuticals and crop protection technologies; and Industrial Specialties, serving niche markets like coatings and textiles. Croda’s strategy emphasizes "New and Protected Products" (NPP), leveraging proprietary science to command premium pricing and long-term supply agreements. In the competitive landscape, Croda contends with diversified giants such as BASF, Evonik, Givaudan, and Ashland. Unlike its larger, mass-market peers, Croda maintains a distinct market position as a specialized, innovation-led partner that prioritizes technical depth and sustainability over commodity scale. The company was founded in 1925 by Henry James Dawe and George William Crowe, originally focusing on lanolin refining. Today, it is led by Group Chief Executive Steve Foots, a 30-year veteran of the firm who has served as CEO since 2012 and is credited with pivoting the group toward life sciences and high-growth consumer actives. The leadership team includes Chief Financial Officer Stephen Oxley, who joined in 2024 with extensive PLC finance experience, and Dr. Thomas Riermeier, who was appointed President of Life Sciences in 2025 following a senior leadership tenure at Evonik. The board is chaired by Danuta Gray, a seasoned executive with deep international governance expertise, and includes notable members such as Jill Anderson, the former CFO of GSK’s R&D division, who joined as a non-executive director in early 2026. This leadership core combines deep internal institutional knowledge with high-level external pedigree in pharmaceuticals and global finance.